tirzepatide in heart failure 💊 New research obesity & The SUMMIT study looked at tirzepatide, a once-weekly injection, in people with both obesity and heart failure with preserved ejection fraction (HFpEF). Over 52 Tirzepatide and Cardiovascular Outcomes: A

Ozempic patient information leaflet

Nausea and emesis are a barrier to GLP-1 receptor agonist therapy, and in the central nervous system GIP receptor agonism appears to attenuate nausea and suppress appetite, features that also help GLP-1 receptor agonism promote a negative energy balance

This allows them to monitor your potassium and blood sugar levels more closely and ensure your routine is safe

This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns

Montenero A, Kearney A, Mulugeta M, et al

Shima Hadidchi, MD, Family Practice, is ready to assist you